On October 12, 2026 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, reported financial results for the fiscal quarter ended August 31, 2026, and highlighted significant corporate updates on partnered clinical programs and its wholly owned oncology portfolio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "At the same time, Sanofi advanced our oral STAT6 degrader into the clinic, and we advanced our CBL-B inhibitor NX-1607 into Phase 1b expansion cohorts across four solid tumor indications."

Program Highlights*

Oncology Pipeline

Bexobrutideg Global Collaboration with Roche

During the quarter, Nurix and Roche entered into the global collaboration to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology and neurology, cleared the Hart-Scott-Rodino requirement, and began executing with the initiation of the Phase 3 DAYBreak CLL-306 study. The collaboration is designed to support Nurix’s comprehensive clinical development strategy spanning multiple hematologic malignancies and expansion into immune-mediated diseases, including chronic spontaneous urticaria (CSU) and multiple sclerosis (MS). Under the agreement, development costs are shared 40% by Nurix and 60% by Roche; profits and losses in the United States will be shared equally; and Nurix is eligible to receive tiered royalties on ex-U.S. sales.

Bexobrutideg Registrational Development in CLL/SLL

Enrolled the first patient in DAYBreak CLL-306 (NCT07516093), the first Phase 3 trial of bexobrutideg. The global, randomized registrational study is designed to evaluate the potential superiority of bexobrutideg versus pirtobrutinib in approximately 620 patients with relapsed/refractory CLL/SLL whose disease has progressed following prior covalent BTK inhibitor therapy.
Patients in DAYBreak CLL-306 are randomized 1:1 to receive bexobrutideg 600 mg orally once daily or pirtobrutinib. The dual primary endpoints are objective response rate and progression-free survival, each assessed by an independent review committee. The study is designed to support global regulatory submissions.
Continued enrollment in DAYBreak CLL-201 (NCT07221500), the pivotal single-arm Phase 2 trial designed to support a potential Accelerated Approval submission in patients with relapsed/refractory CLL whose disease has progressed following treatment with a covalent BTK inhibitor, a BCL2 inhibitor and a non-covalent BTK inhibitor.

Bexobrutideg Combination Development

Initiated recruiting for the Phase 1b/2 NX-5948-203 study (NCT07520006), which will evaluate bexobrutideg in combination with standard-of-care therapies in patients with CLL/SLL.
The initial cohort is designed to evaluate bexobrutideg in combination with venetoclax.

Bexobrutideg Clinical Data Presented at EHA (Free EHA Whitepaper) 2026

Presented updated Phase 1a results from the NX-5948-301 study in heavily pretreated relapsed/refractory CLL/SLL demonstrating a median progression-free survival of 22.1 months and an objective response rate of 83.0%. Responses were observed across patients with BTK inhibitor resistance mutations, high-risk molecular features and central nervous system involvement.
Presented new Phase 1b data supporting activity in earlier lines of therapy achieving an objective response rate of 92.9% in patients previously treated with a BTK inhibitor but naïve to BCL2 inhibitor therapy, with 18 of 19 patients remaining on treatment at the data cutoff. Among evaluable BTK inhibitor-naïve patients including treatment-naïve patients, the objective response rate was 84.2%, with 19 of 20 patients remaining on treatment at the data cutoff.
Across 142 Phase 1a/1b CLL patients, bexobrutideg was well tolerated, consistent with prior disclosures. No dose-limiting toxicities or treatment-related Grade 5 adverse events were reported, and treatment discontinuations due to adverse events occurred in 5.6% of patients as of the January 1, 2026 data cutoff.

Oncology Portfolio

Nurix advanced NX-1607, an oral CBL-B inhibitor, into Phase 1b monotherapy expansion cohorts and a Phase 1a combination cohort with pembrolizumab. Nurix enrolled its first patient in both the Phase 1b monotherapy expansion and Phase 1a combination cohorts in September 2026. The expansion cohorts will evaluate NX-1607 in patients with microsatellite stable colorectal cancer (MSS CRC), non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (CRPC) and metastatic melanoma. Each tumor-specific cohort is planned to enroll approximately 30 patients.
Nurix announced the achievement of a $7 million milestone under the strategic collaboration with Pfizer.
Nurix and Gilead agreed to extend the research term for one oncology program by an additional two years. Nurix will receive a one-time fee of $10.0 million in connection with the extension.
Nurix made the decision to discontinue further clinical development of NX-2127 (zelebrudomide) as part of a strategic prioritization of its wholly owned oncology portfolio. Patients currently receiving NX-2127 may continue treatment for as long as clinically appropriate. Nurix will conduct essential safety monitoring while patients remain on treatment, and each treating institution will provide follow-up under its standard of care.

Immunology and Inflammation Pipeline

Expansion of Bexobrutideg into Immunology and Neurology

Completed evaluation of bexobrutideg in a single-ascending-dose and multiple-ascending-dose study in healthy volunteers (NCT06717269) to support future development in immunology and neurology indications.

Immunology and Inflammation Collaboration Programs

Sanofi initiated a Phase 1 first-in-human clinical trial of SAR448272/NX-3911, an oral STAT6 degrader being developed for type 2 inflammatory diseases, triggering a $10 million development milestone payment to Nurix. Following the milestone, Nurix has earned approximately $139 million under its collaboration with Sanofi and remains eligible to receive approximately $455 million in future development, regulatory and commercial milestone payments associated with the STAT6 program, in addition to potential royalties on future product sales. Nurix also retains an option to co-develop, co-promote and share profits and losses for the program equally in the United States following demonstration of clinical proof of concept.
Gilead continues to advance the IRAK4 degrader GS-6791 in an ongoing first-in-human Phase 1 study in healthy volunteers. Nurix retains the right to opt in after Phase 1 to a 50/50 U.S. profit share and co-development arrangement, subject to certain restrictions.

*Expected timing of events throughout this press release is based on calendar year quarters.

Fiscal Third Quarter 2026 Financial Results

Revenue for the three months ended August 31, 2026, was $673.1 million compared with $7.9 million for the three months ended August 31, 2025. The increase was primarily due to $653.2 million of license revenue from the collaboration with Roche and $10.0 million from the achievement of a development milestone from the collaboration with Sanofi.

Research and development expenses for the three months ended August 31, 2026, were $79.3 million compared with $86.1 million for the three months ended August 31, 2025. The decrease was primarily due to the cost sharing offset related to the collaboration with Roche.

General and administrative expenses for the three months ended August 31, 2026, were $34.4 million compared with $13.2 million for the three months ended August 31, 2025. The increase was primarily due to one-time expenses associated with the Roche transaction for consulting costs and business development activities.

Net income for the three months ended August 31, 2026, was $549.8 million, or $4.73 per diluted share, compared with net loss of $86.4 million, or ($1.03) per basic and diluted share, for the three months ended August 31, 2025.

Cash, cash equivalents and marketable securities were $1.1 billion as of August 31, 2026, compared with $592.9 million as of November 30, 2025.

About Bexobrutideg (NX-5948)

Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche across malignant hematology, immunology and neurology.

Bexobrutideg is currently being evaluated in a broad clinical development program in patients with CLL, including DAYBreak CLL-201 (NCT07221500), a pivotal single-arm Phase 2 study in relapsed/refractory CLL; DAYBreak CLL-306 (NCT07516093), a randomized Phase 3 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL; NX-5948-203 (NCT07520006), a Phase 1b/2 study evaluating bexobrutideg in combination with venetoclax with or without an anti-CD20 antibody in relapsed/refractory and treatment-naïve CLL; and NX-5948-301 (NCT05131022), a Phase 1a/1b study in relapsed/refractory B-cell malignancies. Additional information about these clinical trials can be found at clinicaltrials.gov.

(Press release, Nurix Therapeutics, OCT 12, 2026, View Source [SID1234673342])

On October 12, 2026 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, reported that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved the registrational Phase III study of the Company’s novel BCL2 inhibitor mesutoclax (ICP-248) in combination with orelabrutinib for the treatment of patients with marginal zone lymphoma (MZL) who have received at least one prior therapy. This marks the fifth registrational clinical trial initiated for mesutoclax.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mesutoclax is a novel, oral BCL2 inhibitor developed by InnoCare that can exert anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells.

Mesutoclax is accelerating multiple clinical trials in B-cell lymphomas and myeloid malignancies, with five registrational clinical trials currently underway. The Phase III trial of mesutoclax with orelabrutinib in 1L CLL/SLL has completed patient enrollment. The registrational Phase II clinical trial of mesutoclax in BTK inhibitor-treated mantle cell lymphoma (MCL) has completed patient enrollment. The head-to-head registrational Phase III trial of mesutoclax with azacitidine versus venetoclax with azacitidine in treatment naïve (TN) acute myeloid leukemia (AML) was initiated in China. The registrational Phase III clinical trial of mesutoclax in combination with orelabrutinib in r/r MCL is ongoing in China. In addition, global clinical development of mesutoclax in AML and myelodysplastic syndrome (MDS) is accelerating in China, the U.S., and Australia.

Mesutoclax in combination with orelabrutinib has been granted BTD in China for the treatment of patients with MZL who have received at least one prior therapy. Data presented at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting demonstrated that the combination achieved an ORR of 100%, with an excellent efficacy and safety, in this patient population.

Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, "As the first BCL2 inhibitor granted Breakthrough Therapy Designation (BTD) in China, mesutoclax has rapidly advanced across multiple clinical programs throughout China and globally, positioning it to become a globally competitive innovative therapy, further consolidating the Company’s leading position in hemato-oncology. We will continue to accelerate our clinical trials to provide better treatment options for more patients as soon as possible."

Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin’s lymphoma (NHL). It is the second most prevalent lymphoma in China, accounting for 8.3% of all lymphomas. It mainly affects the middle-aged and elderly people. The annual incidence of MZL has increased globally.

(Press release, InnoCare Pharma, OCT 12, 2026, View Source [SID1234673341])

On October 12, 2026 Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences" or the "Company")(SSE: 688321) reported that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for CS43158 tablets, a new molecular entity for the treatment of acute myeloid leukemia (AML), discovered through the company’s AI-enabled Chemical Genomics Platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AML is the most common type of acute leukemia in adults. It’s a highly heterogeneous disease with limited treatment options and high relapse risks. FLT3 mutations are key oncogenic drivers and occur in approximately 35%–45% of patients with relapsed/refractory (R/R) AML. The efficacy of currently approved FLT3 inhibitors as monotherapy remains limited, with a 30-40% objective response rate (ORR), a median progression-free survival (mPFS) of 2-6 months; approximately 60-80% of patients develop resistance within 6–12 months due to activation of bypass pathways, secondary mutations, and clonal evolution. Therefore, developing next-generation drugs that simultaneously inhibit FLT3 driver mutations and multiple bypass resistance pathways is considered a key strategy for overcoming current treatment limitations.

CS43158 is a multikinase inhibitor with global patent protection, independently developed by Chipscreen Biosciences leveraging its AI-ChemGen Platform. It employs a distinctively synergistic multi-target inhibition strategy that not only broadly suppresses FLT3 signaling but also precisely targets bypass resistance pathways. CS43158 shows potent inhibitory activity against clinically relevant FLT3 alterations, including wild-type FLT3 overexpression, FLT3-ITD, and FLT3-TKD mutations. Meanwhile, it also suppresses aberrant activation of cytokine- and growth factor-associated signaling pathways within the bone marrow microenvironment, thereby broadly blocking non-FLT3-dependent tumor cell survival and proliferation pathways.

Preclinical studies indicate that CS43158 has favorable pharmacokinetics and a favorable safety profile, and exhibits superior antitumor activity over reference compound across multiple models. In resistant models of existing therapies, sequential treatment with CS43158 significantly suppresses tumor progression, demonstrating its robust potential to overcome clinical resistance. Furthermore, CS43158 demonstrates clear synergy with BCL-2 inhibitors, providing strong preclinical rationale for future combination regimens in AML.

CS43158 has the potential to pair the precision of targeted therapy with durable control of drug resistance. This approach may further enhance antitumor activity, overcome or delay resistance to FLT3 inhibitors, and offer AML patients a differentiated therapeutic option for durable clinical benefit.

About the AI-enabled Chemical Genomics Platform

True to its name, Chipscreen Biosciences has been building a chemical genomics-based platform since its founding in 2001. Based on gene expression profiling analysis through microarray technology, this platform systematically evaluates efficacy- and safety-related biological activities, thereby supporting screening and evaluation in early-stage small-molecule drug discovery. To convert the biological effects of drug molecules into computable data, Chipscreen Biosciences has established its AI-ChemGen Platform by integrating internal and external expertise over the past two decades. Furthermore, to solve the verifiable data bottleneck, the Company has been building a structured and traceable proprietary database leveraging interdisciplinary approaches in cheminformatics and bioinformatics to bridge the closed loop of "data-model-wet lab-clinical trial". Several molecules based on AI-ChemGen Platform have entered the global clinical development.

(Press release, Shenzhen Chipscreen Biosciences, OCT 12, 2026, View Source [SID1234673339])

On October 12, 2026 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), reported final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one of the largest real-world evaluations of mogamulizumab in Germany and add to the growing body of evidence supporting its use in routine clinical practice.1-3

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conducted as a company-sponsored, multicentric, non-interventional, combined retro-prospective real-world study across 18 centres throughout Germany, MINT brought together cutaneous T‑cell lymphoma (CTCL) specialists to evaluate treatment outcomes with mogamulizumab in a real-world setting, with time-to-next-treatment (TTNT) as the study’s primary endpoint.1 The study captured a broad and heterogeneous patient population, including clinically relevant subgroups such as patients with large cell transformation (LCT) and folliculotropic mycosis fungoides (fMF), and stratified by disease stage and mogamulizumab-associated rash (MAR) status, providing insights that complement evidence generated through controlled clinical studies.1,4

MF and SS are forms of CTCL, a type of non-Hodgkin’s lymphoma that manifests on the skin,5 though the disease can also involve the blood, lymph nodes and visceral organs.6 Symptoms can include persistent, itchy and scaly rashes, changes in skin colour and patches, plaques and/or tumours.7 These visible and often difficult-to-hide symptoms can make everyday activities harder and significantly affect patients’ quality of life, including their work, relationships and social lives,8 and for some patients the disease can progress to affect long-term survival.9

"For patients living with mycosis fungoides and Sézary syndrome, understanding how treatments perform outside the controlled setting of clinical trials is critically important. The final MINT results demonstrate meaningful clinical outcomes across a broad patient population treated in routine practice and highlight the value of collaborative real-world research in helping clinicians make informed treatment decisions," said Professor Chalid Assaf, Director of the Department of Dermatology and Venereology, Helios Klinikum Krefeld, Health and Medical University Düsseldorf-Krefeld, Germany.

The final analysis included 109 patients, comprising 56 patients with MF and 53 patients with SS, with a median follow-up of 25.2 months.1 The majority of patients had advanced disease when they started treatment, with 83.5% at stage IIB or above.1 The study demonstrated durable treatment outcomes, reporting a median TTNT of 14.9 months, a best overall response rate of 62.4%, and an overall median progression-free survival of 20.2 months.1 Median overall survival was not estimable at the time of analysis due to the limited number of deaths observed, despite up to 71 months of follow-up in some cases.1

Looking more closely at treatment response in clinically relevant patient subgroups, exploratory analyses reported best overall response rates of 54.5% in patients with LCT (n=11; 95% CI: 23.4–83.3) and 50.0% in patients with fMF (n=12; 95% CI: 21.1–78.9). Additional exploratory analyses by disease stage showed best overall response rates of 50% in patients with early-stage disease (n=18; 95% CI: 26.0–74.0) and 64.8% in patients with advanced stage disease (n=91; 95% CI: 54.1–74.6).10 Disease control rate was also reported in patients with MAR (n=47), at 95.7%.4

TTNT is an important measure in real-world clinical practice as it reflects both disease control and the duration of clinical benefit before a patient requires an alternative treatment approach. The study reported a median TTNT of 12.0 months in patients with MF and 20.2 months in patients with SS.4 Patients also experienced improvements in quality of life, with median Skindex-29 scores improving by 38.5% from 49.1 at treatment initiation (n=21) to 30.2 at Month 12 (n=7).1

"MINT provides valuable real-world evidence from Germany on the use of mogamulizumab across the heterogeneous population of patients with mycosis fungoides and Sézary syndrome, including clinically relevant subgroups that are often underrepresented in clinical trials. By evaluating time-to-next-treatment as a clinically meaningful outcome, the study offers practical insights that can support CTCL specialists in making informed, individualised treatment decisions," said Dr. Azeem Danish, Medical Affairs Director, DACH, Kyowa Kirin.

The investigators concluded that, in a real-world setting, mogamulizumab demonstrated a safety profile comparable to that observed in the pivotal Phase 3 MAVORIC study, while providing clinical benefits in treatment response and quality of life for patients with MF and SS.1,5 Grade 3 or higher treatment-related adverse events were reported in 38.5% of patients, most commonly drug eruption and lymphopenia.1 Serious treatment-related adverse events leading to discontinuation occurred in 22.0% of patients.1

Kyowa Kirin has supported the generation of real-world evidence in CTCL through collaborations with investigators and treatment centres across Europe. The MINT study contributes to a growing evidence base exploring outcomes in patients treated with mogamulizumab in routine clinical practice1-3 and reflects a shared commitment between investigators and industry to advancing understanding of rare cancers and improving care for patients living with CTCL.

About the MINT Study

MINT (Mogamulizumab In a Non-interventional study to evaluate the safety and outcome in mycosis fungoides and Sézary syndrome Treatment) is a German multicentric, non-interventional, retro-prospective real-world study evaluating the effectiveness and tolerability of mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Data were collected from patient medical records across 18 study sites in Germany. The primary endpoint was time-to-next-treatment, with secondary endpoints including response rate, progression-free survival, overall survival, quality of life and tolerability.

(Press release, Kyowa Hakko Kirin, OCT 12, 2026, View Source [SID1234673338])

On October 12, 2026 Invenra Inc., a biotechnology company developing multispecific antibody therapeutics, reported the launch of its first 52 Views of Cancer, a playing card deck showcasing original artwork by people affected by cancer. Invenra is debuting the deck at the World ADC Conference in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The project links cancer journeys directly to researchers, clinicians, and drug developers. The launch also marks the company’s expansion into antibody-drug conjugate (ADC) asset discovery, using its powerful B-Body bispecific and T-Body trispecific antibody discovery platforms to create next-generation multispecific ADC assets for development with biopharma partners.

Art connects patients and researchers

Each of the deck’s 52 cards, along with the jokers and box cover, features original artwork contributed by a different cancer patient, survivor, or family member. Together, the works celebrate the creativity, resilience, and spirit of people whose lives have been touched by cancer.

"Through this project, we want to bring the experiences of people affected by cancer into the conversations shaping new cancer therapies," said Roland Green, Invenra CEO and founder. "The deck also introduces our work in antibody-drug conjugates. Invenra is developing ADCs for a wide variety of cancers, including ovarian, breast, lung, colon, neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing’s sarcoma, diffuse midline glioma, and glioblastoma."

Invenra licensed the artwork and offered an honorarium to each featured artist. The artwork and accompanying stories are available on the 52 Views project website.

Invenra is sharing the decks at the conference and other major scientific and medical conferences, placing patients’ voices and perspectives directly in the hands of researchers, clinicians, and scientists working to cure the cancers these artists have experienced.

Advancing multispecific ADC discovery

The Invenra ADC discovery program combines its collection of antibody binders with proprietary multispecific platforms to develop candidates that enable access to broader patient populations with wider coverage by targeting multiple tumor targets.

Additionally, the company’s T-Body platform supports development of trispecific constructs incorporating HYPER-Internalization mechanisms, which can increase internalization, delivering more payload to cells while simultaneously targeting multiple pathways to reduce tumor escape routes.

On October 13, 2026, at the World ADC Conference, Bonnie Hammer, PhD, Invenra Executive Vice President of R&D, will present new preclinical data on the company’s ADC programs. In her talk, entitled From Bispecific to Trispecific Antibodies: Reimagining the Next Generation of ADCs, Hammer outlines a novel HER2 × HER2 × HER3 T-Body trispecific antibody, which combines three binders to target breast cancer.

"The preclinical data demonstrate the amazing potential of trispecific ADCs," said Hammer. "Invenra is exploring how trispecific targeting can improve payload delivery and address signaling pathways that may contribute to treatment resistance."

(Press release, Invenra, OCT 12, 2026, View Source [SID1234673337])